Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080044 | 0.89 | DGAT1 (0.45) | DGAT1TP53RAB9ALMNAKMT2A | |
| SCHEMBL1578569 | 0.82 | PKM (0.41) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL18735658 | 0.81 | L3MBTL1 (0.39) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL191649 | 0.80 | CA12 (0.41) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL1579422 | 0.75 | TDP1 (0.43) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL13324201 | 0.75 | DGAT1 (0.46) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL487344 | 0.75 | DGAT1 (0.46) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL24074502 | 0.72 | TDP1 (0.36) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL5498919 | 0.71 | DGAT1 (0.48) | DGAT1KMT2ACA12CA14CA2 | |
| SCHEMBL20125284 | 0.71 | TDP1 (0.43) | DGAT1KMT2ACA12CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AAAS, MGAM, PAM | DGAT1 2035/4885TP53 4819/4885RAB9A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.